By Integrated Care Journal-
There is a critical public health need to get ahead of the current spread of Covid-19 with fast and simple testing for all. To address this need Siemens Healthineers is launching a rapid and easy-to-use antigen test for the detection of SARS-CoV-2 in the United Kingdom and other CE countries. The CLINITEST Rapid COVID-19 Antigen Test is a point-of-care cassette test that does not require laboratory instruments or specialised lab personnel to administer, and it delivers results in 15 minutes.
The CE marked test, which has been developed and tested by a Siemens Healthineers partner, demonstrated 96.72 per cent sensitivity and 99.22 per cent specificity based on a clinical study of 317 subjects. The study was performed using operators with varied credentials at six diverse sites including a hospital, a community clinic, a college campus, and an oncology unit. Siemens Healthineers intends to meet such testing demand as the pandemic evolves. There are also plans to submit the test for FDA Emergency Use Authorisation in the USA.
“There is a great public need for reliable tests that can quickly identify contagious individuals and help to minimise the spread of COVID-19, especially in high-traffic areas and where people commonly congregate,” commented Stewart Hutton, Head of Point of Care Diagnostics at Siemens Healthineers GB&I.
Mr Hutton continued to say that: “with quality at the forefront of decision-makers’ criteria to determine test reliability, it was critical the clinical study for this test assessed variable clinical conditions that can be expected when implementing a rapid antigen test. Siemens Healthineers is committed to supporting the UK’s national testing strategy and this rapid antigen test makes testing available to more people across a wider variety of settings. This is particularly applicable to locations that need to test people quickly such as airports or those that have limited access to laboratory resources such as schools. ”
The CLINITEST Rapid COVID-19 Antigen Test is easy to administer for healthcare professionals and doesn’t require specialized laboratory personnel or instruments and offers flexibility to test in locations that can’t always benefit from immediate results. Results are delivered quickly using the nasopharyngeal swab method. Once a sample is collected, the swab is inserted into a tube with a special liquid to extract the target molecule. This liquid is then dispensed onto a test cassette and, in 15 minutes, a positive or negative result is clearly indicated.
In addition to the CLINITEST Rapid COVID-19 Antigen Test, Siemens Healthineers offers an extensive diagnostics portfolio to aid in the prognosis, treatment and follow up of COVID-19 patients. This test adds to the 15 critical assays Siemens Healthineers offers to detect severe symptoms and better manage critical COVID-19 patients. The company’s broad and differentiated menu includes antibody and molecular SARS-CoV-2 tests, and haematology, coagulation, cardiac, respiratory, inflammation and infectious disease panels. Blood gas and imaging solutions from Siemens Healthineers deliver actionable results that aid clinicians in caring for Covid-19 patients.
The CLINITEST Rapid test is to be launched in the United Kingdom and other CE mark countries; plans to submit to FDA for Emergency Use Authorisation in the USA.
Further information is available at www.siemens-healthineers.co.uk.
#PPP #ACJDigital #siemenshealthineers #ACJPartner #ACJInsight #coronavirus